000			a
999			_c16836 _d16836
003			OSt
005			20220623121743.0
008			220623b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_916733 _aVardhipathi, Sravana Swathi
245			_aRetrospective pharmacovigilance analysis of nonsteroidal anti-inflammatory drugs-induced chronic kidney disease
250			_aVol.53(3), May-June
260			_aMumbai _bWolter Kluwer _c2021
300			_a192-197p.
520			_aBACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with kidney damage. In India, only a few reports related to the risk of chronic kidney disease (CKD) with NSAIDs are available. The present study highlights the prevalence and pattern of NSAIDs-induced CKD adverse drug reactions in the Indian population. MATERIALS AND METHODS: The individual case safety reports (ICSRs) reported by the National Coordination Centre (NCC)-Pharmacovigilance Program of India to the Uppsala monitoring center Pharmacovigilance database system “VigiLyze” were analyzed by using the preferred term “Chronic Kidney Disease” and “NSAIDs” from July 1, 2011 to September 12, 2019. A total of 28 ICSRs of NSAIDs associated CKD ICSRs were analyzed retrospectively for age, gender, concomitant medication, seriousness, and other criteria. RESULTS: About 82% of CKD cases due to NSAIDs were in the age group of 40–80 years, in which 54% belong to male. About 43% of the patients had CKD due to the use of diclofenac, and almost 96% of the patients had oral dosage forms of NSAIDs. The main indications of NSAIDs in these CKD cases were generalized body pain and joint pain. About 79% case of NSAID-induced CKD were serious, among which 54% led to the hospitalization and further use of NSAIDs discontinued in 86% of CKD cases.
650		0	_94774 _aPHARMACOLOGY
700			_916734 _aSaroha, Shrishti
773	0		_dAndheri - Mumbai Wolters Kluwer India Private Limited _x0253-7613 _tIndian Journal of Pharmacology
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262424/ _yClick here
942			_2ddc _cAR